Drug Profile
EDC 9
Alternative Names: EDC-9; ProxAlphaLatest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Centrose
- Class Antineoplastics; Drug conjugates; Glycosides; Immunoconjugates; Monoclonal antibodies; Steroids
- Mechanism of Action B cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diffuse large B cell lymphoma
Highest Development Phases
- Preclinical Diffuse large B cell lymphoma
Most Recent Events
- 01 Sep 2023 EDC 9 is still in preclinical phase for Diffuse large B cell lymphoma in USA (Parenteral) (Centrose pipeline; September 2023)
- 01 Aug 2017 Centrose has patent protection for extracellular drug conjugate technology in Japan
- 01 Aug 2017 Centrose has patents pending for extracellular drug conjugate technology in World